Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer

Magnetic resonance-guided radiation therapy (MRgRT) has recently become available in clinical practice and is expected to expand significantly in coming years. MRgRT offers marker-less continuous imaging during treatment delivery, use of small clinical target volume (CTV) to planning target volume (...

Full description

Saved in:
Bibliographic Details
Published in:Physics and imaging in radiation oncology Vol. 9; pp. 69 - 76
Main Authors: Tetar, Shyama U., Bruynzeel, Anna M.E., Lagerwaard, Frank J., Slotman, Ben J., Bohoudi, Omar, Palacios, Miguel A.
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 01.01.2019
Elsevier
Subjects:
MR-guided Radiotherapy (MRgRT)
On-table adaptation
Original
Prostate cancer
Stereotactic body radiotherapy (SBRT)
Workflow
Stereotactic body radiotherapy (SBRT)
Workflow
MR-guided Radiotherapy (MRgRT)
On-table adaptation
Prostate cancer
ISSN:2405-6316, 2405-6316
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Magnetic resonance-guided radiation therapy (MRgRT) has recently become available in clinical practice and is expected to expand significantly in coming years. MRgRT offers marker-less continuous imaging during treatment delivery, use of small clinical target volume (CTV) to planning target volume (PTV) margins, and finally the option to perform daily plan re-optimization. A total of 140 patients (700 fractions) have been treated with MRgRT and online plan adaptation for localized prostate cancer since early 2016. Clinical workflow for MRgRT of prostate cancer consisted of patient selection, simulation on both MR- and computed tomography (CT) scan, inverse intensity-modulated radiotherapy (IMRT) treatment planning and daily plan re-optimization prior to treatment delivery with partial organs at risk (OAR) recontouring within the first 2 cm outside the PTV. For each adapted plan online patient-specific quality assurance (QA) was performed by means of a secondary Monte Carlo 3D dose calculation and gamma analysis comparison. Patient experiences with MRgRT were assessed using a patient-reported outcome questionnaire (PRO-Q) after the last fraction. In 97% of fractions, MRgRT was delivered using the online adapted plan. Intrafractional prostate drifts necessitated 2D-corrections during treatment in approximately 20% of fractions. The average duration of an uneventful fraction of MRgRT was 45 min. PRO-Q’s (N = 89) showed that MRgRT was generally well tolerated, with disturbing noise sensations being most commonly reported. MRgRT with daily online plan adaptation constitutes an innovative approach for delivering SBRT for prostate cancer and appears to be feasible, although necessitating extended timeslots and logistical challenges.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2405-6316
2405-6316
DOI:10.1016/j.phro.2019.02.002